| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12282-011-0266-5 |
| P8608 | Fatcat ID | release_jvzoqhpqynck3lqlqr7wnzuuue |
| P698 | PubMed publication ID | 21526426 |
| P50 | author | Kiyohiko Hatake | Q88491888 |
| Yoshinori Ito | Q114815707 | ||
| Takuji Iwase | Q114816021 | ||
| P2860 | cites work | A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | Q24647928 |
| Therapeutic antibody targeting of individual Notch receptors | Q27660544 | ||
| Hedgehog Pathway Antagonist 5E1 Binds Hedgehog at the Pseudo-active Site | Q27661941 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Identification of selective inhibitors of cancer stem cells by high-throughput screening | Q28255115 | ||
| The difficulty of targeting cancer stem cell niches | Q28744461 | ||
| Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy | Q29617584 | ||
| Genomic and transcriptional aberrations linked to breast cancer pathophysiologies | Q29619120 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies | Q31003726 | ||
| The mammary gland "side population": a putative stem/progenitor cell marker? | Q33214923 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| More than markers: biological significance of cancer stem cell-defining molecules | Q33661278 | ||
| Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer | Q33766941 | ||
| Targeting Hedgehog--a cancer stem cell pathway | Q33925257 | ||
| Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer | Q40839204 | ||
| Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. | Q42438785 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer | Q42499457 | ||
| Stem cells: Cues from steroid hormones | Q43036665 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| Fifteen-year trends in metastatic breast cancer survival in Greece | Q43241613 | ||
| Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group | Q43289851 | ||
| Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. | Q46365348 | ||
| Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies | Q46446226 | ||
| HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer | Q46713075 | ||
| Gene expression profiling of primary breast carcinomas using arrays of candidate genes | Q47807811 | ||
| Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. | Q54732957 | ||
| Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an | Q57578399 | ||
| Survival differences among women with de novo stage IV and relapsed breast cancer | Q34231099 | ||
| Is breast cancer survival improving? | Q34285880 | ||
| A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells | Q34787867 | ||
| Measuring proliferation in breast cancer: practicalities and applications | Q35633693 | ||
| uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues | Q35720929 | ||
| International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? | Q35820247 | ||
| Survivin, a cancer target with an emerging role in normal adult tissues | Q36491426 | ||
| Bone marrow cells in the 'pre-metastatic niche': within bone and beyond | Q36691234 | ||
| Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? | Q36814227 | ||
| Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues | Q36930838 | ||
| Mammary stem cells and breast cancer--role of Notch signalling. | Q36943351 | ||
| PARP inhibitor development for systemic cancer targeting | Q36952027 | ||
| Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies | Q37009796 | ||
| HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. | Q37015151 | ||
| Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials | Q37202470 | ||
| International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy | Q37329165 | ||
| Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs | Q37336482 | ||
| Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients | Q37360176 | ||
| Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells | Q37360230 | ||
| Resistance to endocrine therapy: are breast cancer stem cells the culprits? | Q37404590 | ||
| Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer | Q37467531 | ||
| Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients | Q37480512 | ||
| Overcoming drug resistance by enhancing apoptosis of tumor cells. | Q37481518 | ||
| Bmi-1, stem cells and cancer | Q37541792 | ||
| The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review | Q37555191 | ||
| Breast cancer stem cells. | Q37608970 | ||
| Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis | Q37619348 | ||
| Epithelial-mesenchymal transition in cancer development and its clinical significance | Q37644546 | ||
| Ki67 in breast cancer: prognostic and predictive potential | Q37691691 | ||
| Targeting Notch to target cancer stem cells. | Q37763414 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| Cancer stem cells and self-renewal. | Q37763416 | ||
| Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients | Q39676823 | ||
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 | ||
| Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab | Q39874714 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 206-211 | |
| P577 | publication date | 2011-04-28 | |
| P1433 | published in | Breast Cancer | Q15752871 |
| P1476 | title | Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? | |
| P478 | volume | 19 |
| Q37533025 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer |
| Q49502234 | Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes |
| Q28662207 | Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2 |
| Q34898535 | Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis |
| Q35038699 | Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer |
| Q36234042 | Targeting of Rac GTPases blocks the spread of intact human breast cancer. |
Search more.